N Proportion 95%–CI Effect size 2010–2012 8 7.0 (3.1; 15.1) ——

7.3

6.6

7.5

Patients that discontinued due to adverse events by year category for phase 2 trials

Test for subgroup differences: p = 0.417

(6.9; 14.8)

(5.3; 10.1)

(4.5; 9.6)

(6.1; 9.2)

(2.5; 20.7)

-

-

Effect size (95%-CI)

40

13 10.2

24

19

64

2013-2015

2016-2019

2019-2021

Prediction interval

Overall